| Value | ₹2,000 Cr |
|---|
BSE filing, NSE: IIFLCAPS. Summary written from the filing by ALFA Finder's alert engine.
IIFL Capital Services Ltd: key numbers
- Share price
- ₹347.85
- Market cap
- ₹10,970 Cr
- Revenue (annual)
- ₹2,420 Cr
- Net profit (annual)
- ₹561.4 Cr
- P/E (TTM)
- 17.9×Sector 19.8×
- Promoter holding
- 30.49%-0.18% QoQ
- FII holding
- 15.37%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from IIFL Capital Services Ltd
All →IIFL Capital Services Employee Stock Options
IIFL Capital Services granted 29,713 ESOPs and allotted 180,499 shares on exercise under its 2018 ESOS scheme. The equity base rose to 315,532,512 shares of ₹2 each.
IIFL Capital Services Open Offer: ₹3,505 Cr
FIH Mauritius and HWIC launched a 26% open offer for IIFL Capital Services at Rs.350 per share. Up to Rs.3,505 Crore; tendering opens November 2.
- Value
- ₹3,505 Cr
IIFL Capital Services Adverse Business Impact
IIFL Capital Services' subsidiary surrendered its SEBI Investment Adviser registration, effective October 28, 2026. The company states there is no material monetary impact and no penalty.
IIFL Capital Services Results Update
IIFL Capital Services reported consolidated Q2FY27 revenue of ₹722 crore, up 22% year-on-year, with PBT of ₹174 crore. The press release also covers the Fairfax change-in-control and a proposed NBFC subsidiary.
IIFL Capital Services Investor Presentation: Key Takeaways
Q2FY27 revenue ₹7,219 Mn (+22% YoY) and PAT ₹1,266 Mn (+49% YoY). H1FY27 PAT ₹3,108 Mn (+19%). Fairfax to acquire up to 51% with ~₹20 bn capital infusion.
IIFL Capital Services Management Change
IIFL Capital's board appointed Vasudev Jagannath as Additional and Whole-Time Director. He will become Managing Director from January 2027, subject to approvals.
- Execution
- 3 years from appointment
Other fund raise announcements
All →Sudarshan Pharma Industries Fund Raise of ₹72 Cr
Sudarshan Pharma's board approved up to Rs. 72 Crore of preferential convertible warrants for promoters Hemal and Sachin Mehta. Shareholder approval will be sought at an EGM.
- Value
- ₹72.00 Cr
Flywings Simulator Training Centre Fund Raise of ₹68.2 Cr
Flywings Simulator's board approved Rs. 68.20 Crore fully convertible warrants on a preferential basis. Promoter Rupal Mandavia is allotted Rs. 25 Crore, subject to shareholder approval.
- Value
- ₹68.20 Cr
Kanel Industries Fund Raise of ₹16.99 Cr
Kanel Industries' board approved a rights issue of 42.52 lakh equity shares at Rs.39.95 each. The issue aggregates about Rs.16.99 Crore, with record date 13 November 2026.
- Value
- ₹16.99 Cr
- Execution
- Rights issue opens 23 November 2026 and closes 30 November 2026
Sudarshan Pharma Industries Fund Raise
Board approved issuing up to 72 Crore warrants to promoters on a preferential basis. Pricing per Reg 164 is pending, with no fixed rupee value stated.
GAIL (India) Fund Raise
GAIL Board approved in principle the IPO of subsidiary GAIL Gas Limited on Indian exchanges. GAIL will dilute its GGL equity up to 25%.
Gujarat Inject (Kerala) Fund Raise of ₹3 Cr
Gujarat Inject Kerala's board approved a Rs.3 Crore preferential warrant issue to public investors. Authorised capital will rise to Rs.17.63 Crore, subject to shareholder approval.
- Value
- ₹3.00 Cr